医疗研发外包成分股数据 申万3级
851563.SI (27)
数据更新时间：2024-05-17
"-"表示无或者负数
| 序号 | 股票代码 | 股票简称 | 纳入时间 | 申万1级 | 申万2级 | 申万3级 | 价格
|
市盈率
|
市盈率ttm
|
市净率
|
股息率
|
市值（亿元）
|
归母净利润同比增长(03-31)
|
归母净利润同比增长(12-31)
|
营业收入同比增长(03-31)
|
营业收入同比增长(12-31)
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 603456.SH | 九洲药业 | 2023-07-06 | — | — | 医疗研发外包 | 15.92 | 13.86 | 14.47 | 1.65 | 2.5% | 143.20 | -15.65% | 12.17% | -15.73% | 1.44% |
| 2 | 300363.SZ | 博腾股份 | 2014-02-12 | — | — | 医疗研发外包 | 16.15 | 33.05 | — | 1.55 | — | 88.19 | -131.20% | -86.69% | -50.81% | -47.87% |
| 3 | 301520.SZ | 万邦医药 | 2023-10-10 | — | — | 医疗研发外包 | 44.95 | 27.72 | 26.57 | 2.01 | — | 29.97 | 18.81% | 9.48% | 25.14% | 31.07% |
| 4 | 600721.SH | 百花医药 | 2008-01-25 | — | — | 医疗研发外包 | 6.11 | 179.84 | 86.57 | 3.2 | — | 23.33 | 209.02% | 137.31% | 20.03% | 5.54% |
| 5 | 300149.SZ | 睿智医药 | 2010-12-29 | — | — | 医疗研发外包 | 5.18 | — | — | 1.8 | — | 25.89 | 10.87% | -339.83% | -12.68% | -14.19% |
| 6 | 688238.SH | 和元生物 | 2023-09-25 | — | — | 医疗研发外包 | 5.74 | — | — | 1.84 | — | 37.16 | -32.85% | -425.90% | 93.48% | -29.69% |
| 7 | 301096.SZ | 百诚医药 | 2021-12-27 | — | — | 医疗研发外包 | 63.48 | 25.42 | 24.12 | 2.52 | — | 69.14 | 42.06% | 40.07% | 34.04% | 67.51% |
| 8 | 301201.SZ | 诚达药业 | 2022-01-27 | — | — | 医疗研发外包 | 20.63 | 35.08 | 35.47 | 1.42 | 0.91% | 31.92 | -5.09% | -14.56% | -1.28% | 0.69% |
| 9 | 301333.SZ | 诺思格 | 2022-08-09 | — | — | 医疗研发外包 | 43.77 | 25.85 | 26.8 | 2.37 | 0.36% | 42.02 | -19.95% | 43.27% | 10.19% | 13.15% |
| 10 | 301509.SZ | 金凯生科 | 2023-08-10 | — | — | 医疗研发外包 | 37.39 | 25.95 | 30.09 | 2.12 | 1.53% | 45.04 | -58.83% | 7.51% | -41.87% | 7.00% |
| 11 | 300347.SZ | 泰格医药 | 2012-08-24 | — | — | 医疗研发外包 | 56.99 | 24.34 | 29.14 | 2.43 | 0.97% | 492.93 | -58.65% | 0.91% | -8.00% | 4.21% |
| 12 | 688202.SH | 美迪西 | 2023-09-25 | — | — | 医疗研发外包 | 35.74 | — | — | 1.96 | — | 48.13 | -136.98% | -109.82% | -42.51% | -17.68% |
| 13 | 688265.SH | 南模生物 | 2023-09-25 | — | — | 医疗研发外包 | 26.8 | — | — | 1.22 | — | 20.89 | 9.38% | -281.18% | -5.01% | 20.99% |
| 14 | 002821.SZ | 凯莱英 | 2016-11-25 | — | — | 医疗研发外包 | 80.84 | 13.16 | 15.55 | 1.7 | 2.22% | 298.68 | -55.27% | -31.28% | -37.76% | -23.70% |
| 15 | 688131.SH | 皓元医药 | 2023-09-25 | — | — | 医疗研发外包 | 31.77 | 37.49 | 48.77 | 1.88 | — | 47.78 | -63.76% | -34.18% | 20.68% | 38.44% |
| 16 | 688076.SH | 诺泰生物 | 2023-09-25 | — | — | 医疗研发外包 | 56.8 | 74.32 | 58.15 | 5.74 | — | 121.09 | 215.65% | 26.20% | 71.02% | 58.69% |
| 17 | 300759.SZ | 康龙化成 | 2019-02-11 | — | — | 医疗研发外包 | 22.22 | 24.81 | 26.77 | 3.16 | 0.9% | 397.16 | -33.80% | 16.48% | -1.95% | 12.39% |
| 18 | 688046.SH | 药康生物 | 2023-09-25 | — | — | 医疗研发外包 | 11.65 | 30.06 | 30.36 | 2.24 | — | 47.77 | -5.06% | -3.49% | 11.96% | 20.45% |
| 19 | 300404.SZ | 博济医药 | 2015-05-04 | — | — | 医疗研发外包 | 7.83 | 122.96 | 102.79 | 3.12 | 0.12% | 29.93 | 40.67% | -12.04% | 62.08% | 31.19% |
| 20 | 688621.SH | 阳光诺和 | 2023-09-25 | — | — | 医疗研发外包 | 51.93 | 31.48 | 27.75 | 5.73 | — | 58.16 | 51.77% | 18.08% | 8.53% | 37.76% |
| 21 | 300725.SZ | 药石科技 | 2017-11-17 | — | — | 医疗研发外包 | 32.89 | 33.27 | 34.73 | 2.39 | 0.3% | 65.67 | -14.32% | -37.19% | -1.56% | 8.18% |
| 22 | 301257.SZ | 普蕊斯 | 2022-05-24 | — | — | 医疗研发外包 | 44.57 | 20.23 | 20.63 | 2.46 | 0.39% | 27.26 | -10.22% | 86.06% | 17.42% | 29.65% |
| 23 | 688073.SH | 毕得医药 | 2023-09-25 | — | — | 医疗研发外包 | 34.69 | 28.77 | 31.94 | 1.54 | — | 31.53 | -29.39% | -24.94% | 4.05% | 30.94% |
| 24 | 301230.SZ | 泓博医药 | 2022-11-08 | — | — | 医疗研发外包 | 35.95 | 102.85 | 148.75 | 3.51 | 0.99% | 38.69 | -75.99% | -44.00% | 7.69% | 2.26% |
| 25 | 603127.SH | 昭衍新药 | 2017-09-01 | — | — | 医疗研发外包 | 16.9 | 31.92 | — | 1.59 | 1.69% | 126.73 | -244.98% | -63.04% | -12.07% | 4.78% |
| 26 | 603259.SH | 药明康德 | 2018-05-15 | — | — | 医疗研发外包 | 44.9 | 13.71 | 14.04 | 2.37 | 2.0% | 1317.10 | -10.42% | 9.00% | -10.95% | 2.51% |
| 27 | 688222.SH | 成都先导 | 2023-09-25 | — | — | 医疗研发外包 | 13.08 | 128.71 | 81.82 | 3.82 | — | 52.41 | 248.40% | 61.16% | 54.35% | 12.64% |
免责声明：数据相关栏目所收集数据，均来自第三方个人或企业公开数据以及国家统计网站公开发布数据，数据由计算机技术自动收集更新再由作者校验，作者将尽力校验，但不能保证数据的完全准确。 阅读本栏目的用户必须明白，图表所示结果或标示仅供学习参考使用，均不构成交易依据。任何据此进行交易等行为，而引致的任何损害后果，本站概不负责。
关注微信公众号
获取更多数据
获取更多数据
关闭 X